HKSE:08049's Current Ratio is ranked worse than 71.96% of 995
companies
in the Drug Manufacturers industry
Industry Median: 2
vs HKSE:08049: 1.30
Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Jilin Province Huinan Changlong Bio-pharmacy Co Current Ratio Related Terms
Jilin Province Huinan Changlong Bio-pharmacy Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co Current Ratio Chart
Jilin Province Huinan Changlong Bio-pharmacy Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Jilin Province Huinan Changlong Bio-pharmacy Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jilin Province Huinan Changlong Bio-pharmacy Co Current Ratio vs Drug Manufacturers Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) has a Current Ratio of 1.30 as of Dec. 2025. This is 41% below median its historical median of 2.21. Over the past decade, Jilin Province Huinan Changlong Bio-pharmacy Co's Current Ratio has ranged from 1.28 to 5.00. According to the industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #716 out of 995 companies in the Drug Manufacturers industry, placing it in the top 72%.
Is Jilin Province Huinan Changlong Bio-pharmacy Co's Current Ratio too high?
Jilin Province Huinan Changlong Bio-pharmacy Co's current Current Ratio of 1.30 is 41% below median its 10-year median of 2.21. Over the past 10 years, this metric has ranged from a low of 1.28 to a high of 5.00. The Drug Manufacturers industry median Current Ratio is 2.00. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 1.30 is 35% below this industry median. Based on the distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #716 out of 995 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Jilin Province Huinan Changlong Bio-pharmacy Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jilin Province Huinan Changlong Bio-pharmacy Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jilin Province Huinan Changlong Bio-pharmacy Co ranks #716 out of 995 companies for Current Ratio. This places Jilin Province Huinan Changlong Bio-pharmacy Co in the lower half of its industry. The industry median Current Ratio is 2.00. Jilin Province Huinan Changlong Bio-pharmacy Co's value of 1.30 is 35% below this benchmark. Historically, Jilin Province Huinan Changlong Bio-pharmacy Co's own Current Ratio has ranged from 1.28 to 5.00 over the past decade. While the company's 10-year median is 2.21 vs. the industry median of 2.00, Jilin Province Huinan Changlong Bio-pharmacy Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 995 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jilin Province Huinan Changlong Bio-pharmacy Co's current Current Ratio of 1.30 is 35% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jilin Province Huinan Changlong Bio-pharmacy Co's current Current Ratio is 1.30, which is 41% below median its own 10-year median of 2.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jilin Province Huinan Changlong Bio-pharmacy Co stock overvalued right now?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$1.66, compared to a current price of HK$2.31 — trading 39.2% above its estimated fair value. The current Current Ratio is 1.30, which is 41% below median its 10-year median of 2.21 and 35% below the Drug Manufacturers industry median of 2.00. Jilin Province Huinan Changlong Bio-pharmacy Co's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049), the current Current Ratio is 1.30 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jilin Province Huinan Changlong Bio-pharmacy Co (HKSE:08049) Overvalued in 2026?
Based on GuruFocus' analysis, Jilin Province Huinan Changlong Bio-pharmacy Co stock appears to be overvalued.
The current stock price of HK$2.31 is trading 39.2% above its estimated GF Value™ of HK$1.66.
GuruFocus considers Jilin Province Huinan Changlong Bio-pharmacy Co to be Significantly Overvalued.
Key valuation signals for HKSE:08049:
Current Ratio: 1.30 (41% below median its 10-year median of 2.21)
GF Value™: HK$1.66 vs. price of HK$2.31 (39.2% above fair value)
Industry Position: 35% below the Drug Manufacturers median (#716 of 995)
No single metric tells the full story. See the HKSE:08049 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jilin Province Huinan Changlong Bio-pharmacy Co Business Description
Jilin Province Huinan Changlong Bio-pharmacy Co Ltd is principally engaged in the manufacture and distribution of Chinese medicines and pharmaceutical products in the PRC under the brand names of Changlong and Qing Tong. The company has only one business segment. It generates revenue from the Sales of Chinese medicines and pharmaceutical products. Geographically, it derives its entire revenue from the PRC.
81GF Score
Get the complete analysis for HKSE:08049
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08049 has been successfully added to your 
